within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonSteroids.M01AB14_Proglumetacin;

model Proglumetacin
  extends Pharmacolibrary.Drugs.ATC.M.M01AB14;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M01AB14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Proglumetacin is a non-steroidal anti-inflammatory drug (NSAID) of the indoleacetic acid class that is a prodrug of indometacin and proglumide. It was used for the treatment of inflammatory and painful musculoskeletal disorders, such as arthritis, but is not widely used or approved in most countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical healthy adult after oral administration, as no published human PK data are available. Estimates are based on structural similarity to indometacin and general prodrug behavior.</p><h4>References</h4><ol><li><p>Makovec, F, et al., &amp; Setnikar, I (1987). Pharmacokinetics and metabolism of [14C]-proglumetacin after oral administration in the rat. <i>Arzneimittel-Forschung</i> 37(7) 806–813. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3675676/\">https://pubmed.ncbi.nlm.nih.gov/3675676</a></p></li><li><p>Setnikar, I, et al., &amp; Revel, L (1987). Plasma levels of proglumetacin and its metabolites after intravenous or oral administration in the dog. <i>Arzneimittel-Forschung</i> 37(6) 698–702. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3663267/\">https://pubmed.ncbi.nlm.nih.gov/3663267</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Proglumetacin;
